Fracture Repair at the Speed of Light

Our Company » Board of Directors
Eamonn Hobbs | Chairman of the Board, IlluminOss Medical; President & CEO, Digital Cognition Technologies, Inc.
Eamonn Hobbs is President and CEO of Digital Cognition Technologies (DCT), a digital health company with patented technology proven to deliver accurate and objective early indicators of cognitive function. He is also Founder and President of Hobbs Medical Ventures, LLC, a healthcare consulting company. In 2016, Hobbs was appointed as Visiting Scholar, Lecturer and Entrepreneur in Residence at the Translational Accelerator of Brigham and Women’s Hospital, the teaching hospital of Harvard Medical School.Hobbs has had tremendous success in creating and growing companies in to long lasting, financially strong performers. His greatest achievement was AngioDynamics, Inc., which he founded as a division of a public parent company, E-Z-EM, Inc. (NASDAQ: EZEM) and lead through a value-creating carve out tax-free spin-off and simultaneous IPO (NASDAQ: ANGO).Hobbs was elected twice to be Chairman of the Medical Device Manufactures Association (MDMA). He has served on many public and private company Boards, including Antares Pharma, (NASDAQ: ATRS), where he later became interim President and CEO.He holds a B.S. degree in plastics engineering from University of Massachusetts, Lowell.
Manny Avila | President & Chief Executive Officer, IlluminOss  
Manny Avila brings more than two decades of experience in the medical device industry with responsibility for sales, operations and overall business management to IlluminOss. He brings corporate management experience ranging from small start up companies to multi billion dollar global organizations. Prior to joining IlluminOss Mr. Avila served as VP of Global Sales & Marketing at OmniGuide Surgical. Previously he was VP Commercial Operations, Surgical Solutions supporting both the European and US organizations for Covidien, a diversified healthcare company. During this time he spent several years living abroad in Amsterdam and Zurich. He previously spent nine years at Aspect Medical Systems in various positions including VP General Manager International and VP Global Sales Operations. Prior to joining Aspect Medical Systems, Manny was Director, Shared Services for Synthes, VP Manufacturing at AKSYS Ltd. and Director of Operations at Haemonetics.
Daniel Omstead, Ph.D. | Managing Partner, Tekla Capital
Daniel Omstead, Ph.D., is President and CEO of Tekla Capital Management and President of H&Q Lifesciences Investors and H&Q Healthcare Investors; two NYSE listed closed-end mutual funds that make venture and public equity investments in small, emerging healthcare-related companies. Previously, he was President and CEO of Reprogenesis, Inc. a private development stage biotech regenerative medicine company, which merged with two other companies to form Curis, Inc., and was Senior Vice President, R&D at Cytotherapeutics, Inc., a public biotech company in CNS therapies. He holds Doctoral and Master’s Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University.
Rajeev Dadoo, Ph.D.| Partner, SR1
Rajeev joined SR One in 2003 and serves as a director on the boards of IlluminOss Medical and Synovex. He is involved with SR Ones investments in Cydex, Hypnion, Predix Pharmaceuticals, Rib-X Pharmaceuticals, Octoplus, Trigen, Nucleonics, and Pinnacle Pharmaceuticals. He was at the Competitive Excellence Group within GSK working on company-wide strategic projects and also worked at Genentech, in technology and clinical development, and product development. He was a co-founder of Unimicro Technologies, a biomedical analysis company. He received his B.A. in Chemistry and Mathematics from Knox College, an M.B.A. from the Wharton School of the University of Pennsylvania, and his Ph.D. in Chemistry from Stanford University.
Fouad Azzam, Ph.D., MBA | Managing Partner, Life Sciences Partners
Fouad Azzam, PhD, MBA, joined LSP in 2007. He became a General Partner of the firm in that same year. Fouad’s prime focus and responsibility within LSP is to invest in unlisted securities and manage the firm’s North American operations. Prior to joining LSP, Fouad was the Managing Director of Eastman Ventures, the investment arm of Eastman Chemical Company, where he built-up its Healthcare and Advanced Materials practice. In his role as Managing Director, he was responsible for numerous early- and late-stage investments across the US & Europe. Fouad brings a wealth of investment expertise to the LSP team. Prior to his role at Eastman Ventures, Fouad held senior leadership positions at Eastman Chemical including roles in Innovation, Corporate Strategy, Corporate Development (M&A) and New Business Development. His career also includes business, operating, and technology roles at Occidental Chemical and BFGoodrich. Fouad’s academic credentials include a Master’s degree and PhD in Chemical Engineering from the University of Akron in Ohio. In addition, Fouad obtained an MBA in Finance & Strategy from the University at Buffalo in New York.